C07K 2317/82
Functional in the cytoplasm, the inner aspect of the cell membrane, the
Official title: functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
C07K2317/82 (Functional in the cytoplasm, the inner aspect of the cell membrane, the) appears on 37 US grants and 78 published applications in this corpus.
Search patents in C07K- Granted patents
- 37
- Published applications
- 78
- Assignees
- 61
- Inventors
- 191
- Latest grant
- 27 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 1 | 3 |
| 2005 | 0 | 5 |
| 2006 | 0 | 2 |
| 2007 | 2 | 5 |
| 2008 | 0 | 3 |
| 2009 | 0 | 3 |
| 2010 | 0 | 3 |
| 2011 | 1 | 2 |
| 2012 | 0 | 0 |
| 2013 | 2 | 1 |
| 2014 | 3 | 5 |
| 2015 | 1 | 4 |
| 2016 | 3 | 1 |
| 2017 | 1 | 4 |
| 2018 | 3 | 1 |
| 2019 | 1 | 5 |
| 2020 | 5 | 5 |
| 2021 | 3 | 7 |
| 2022 | 1 | 2 |
| 2023 | 2 | 1 |
| 2024 | 0 | 5 |
| 2025 | 2 | 4 |
| 2026 | 0 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Binding proteins 127 May 2025US 12,312,417 B2Nucleus Therapeutics Pty. Ltd
- Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus20 May 2025US 12,304,970 B2Yale University
- Binding proteins 128 Mar 2023US 11,613,590 B2Nucleus Therapeutics Pty. Ltd
- Antibodies and fragments thereof that bind hepatitis B virus protein X14 Feb 2023US 11,578,117 B2Gilead Sciences, Inc.
- Anti-rho GTPase conformational single domain antibodies and uses thereof3 May 2022US 11,319,381 B2Inserm (Institut National De La SantéEt De La Recherche MéDicale)
- Anti-pcna nanobodies, fusion proteins, and uses thereof24 Sep 2026US 2026/0285959 A1Hubei University
- Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators10 Sep 2026US 2026/0265414 A1Yale University
- Mitochondria as a targeted delivery platform3 Sep 2026US 2026/0256940 A1cellvie Inc.
- Antibodies that specifically bind modified oligonucleotides16 Jul 2026US 2026/0201069 A1Hoffmann-La Roche Inc.
- Therapeutic single domain antibody2 Jul 2026US 2026/0184773 A1Singh Biotechnology, LLC
Most cited
By later US patents
- Intracellular targeting of endogenous proteins78US 6,004,940 ADana-Farber Cancer Institute, Inc. · 1999
- Method of intracellular binding of target molecules57US 5,965,371 ADana-Farber Cancer Institute, Inc. · 1999
- Method of intracellular binding target molecules49US 6,329,173 B1Dana-Farber Cancer Institute, Inc. · 2001
- Delivery system using mAb 3E10 and mutants and/or functional fragments thereof31US 7,189,396 B1The Regents of the University of California · 2007
- Humanized antibody and uses thereof29US 6,479,284 B1Avant Immunotherapeutics, Inc. · 2002